The Biden administration on Tuesday unveiled a long-awaited list of the first 10 drugs to be subject to Medicare price negotiations, kicking off a landmark program to reduce drug spending that the pharmaceutical industry is fighting in court.
The drugs — which treat diabetes, cancer and other conditions — are taken by millions of older Americans and cost Medicare billions of dollars annually. The Centers for Medicare & Medicaid Services selects the drugs through a process that prioritizes those that provide the highest Medicare spending, have been on the market for many years and have not yet faced competition from rivals . Additional drugs will be selected for price negotiations in the coming years.
Drugs Selected for Price Negotiations
1. Eliquisfor preventing strokes and blood clotting, from Bristol Myers Squibb and Pfizer
2. Jardiancefor diabetes and heart failure, from Boehringer Ingelheim and Eli Lilly
3. Xarelto, for preventing strokes and blood clotting, from Johnson & Johnson
4. Januviafor diabetes, from Merck
5. Farxigafor diabetes, heart failure and chronic kidney disease, from AstraZeneca
6. interestfor heart failure, from Novartis
7. Enbrelfor arthritis and other autoimmune conditions, from Amgen
8. Imbruvicafor blood cancers, from AbbVie and Johnson & Johnson
9. Stelarafor Crohn’s disease, from Johnson & Johnson
10. Fiasp and NovoLog insulin products, for diabetes, from Novo Nordisk